EP0994717A4 - Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate - Google Patents

Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate

Info

Publication number
EP0994717A4
EP0994717A4 EP98908452A EP98908452A EP0994717A4 EP 0994717 A4 EP0994717 A4 EP 0994717A4 EP 98908452 A EP98908452 A EP 98908452A EP 98908452 A EP98908452 A EP 98908452A EP 0994717 A4 EP0994717 A4 EP 0994717A4
Authority
EP
European Patent Office
Prior art keywords
tolerization
methotrexate
treatment
combination
autoimmune disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98908452A
Other languages
German (de)
English (en)
Other versions
EP0994717A1 (fr
Inventor
Howard L Weiner
Ahmad Al-Sabbagh
Patricia A Nelson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autoimmune Inc
Original Assignee
Autoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autoimmune Inc filed Critical Autoimmune Inc
Publication of EP0994717A1 publication Critical patent/EP0994717A1/fr
Publication of EP0994717A4 publication Critical patent/EP0994717A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
    • B41J2/00—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed
    • B41J2/005—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed characterised by bringing liquid or particles selectively into contact with a printing material
    • B41J2/01—Ink jet
    • B41J2/21—Ink jet for multi-colour printing
    • B41J2/2107—Ink jet for multi-colour printing characterised by the ink properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
    • G06K2215/0082—Architecture adapted for a particular function
    • G06K2215/0094—Colour printing
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
    • G06K2215/0082—Architecture adapted for a particular function
    • G06K2215/0097—Printing on special media, e.g. labels, envelopes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP98908452A 1997-01-24 1998-01-26 Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate Withdrawn EP0994717A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3672297P 1997-01-24 1997-01-24
US36722P 1997-01-24
PCT/US1998/001648 WO1998032451A1 (fr) 1997-01-24 1998-01-26 Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate

Publications (2)

Publication Number Publication Date
EP0994717A1 EP0994717A1 (fr) 2000-04-26
EP0994717A4 true EP0994717A4 (fr) 2000-07-26

Family

ID=21890248

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98908452A Withdrawn EP0994717A4 (fr) 1997-01-24 1998-01-26 Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate

Country Status (10)

Country Link
EP (1) EP0994717A4 (fr)
JP (1) JP2001511134A (fr)
KR (1) KR20000070460A (fr)
AU (1) AU6648898A (fr)
BR (1) BR9807112A (fr)
CA (1) CA2278152A1 (fr)
HU (1) HUP0001960A2 (fr)
IL (1) IL131025A0 (fr)
NO (1) NO993600L (fr)
WO (1) WO1998032451A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068290A2 (fr) 2002-02-11 2003-08-21 Antares Pharma, Inc. Injecteur intradermique
WO2006079064A1 (fr) 2005-01-24 2006-07-27 Antares Pharma, Inc. Injecteur a seringue preremplie assiste d'une aiguille
GB0523576D0 (en) * 2005-11-18 2005-12-28 Theradeas Ltd Drug composition and its use in therapy
US9144648B2 (en) 2006-05-03 2015-09-29 Antares Pharma, Inc. Injector with adjustable dosing
WO2007131013A1 (fr) 2006-05-03 2007-11-15 Antares Pharma, Inc. Injecteur de reconstitution à deux étages
EP2268342B1 (fr) 2008-03-10 2015-09-16 Antares Pharma, Inc. Dispositif de sécurité pour injecteur
WO2010017285A2 (fr) 2008-08-05 2010-02-11 Antares Pharma, Inc. Injecteur à dosage multiple
KR101597672B1 (ko) 2009-03-20 2016-02-25 앤태어스 파머, 인코퍼레이티드 위험 약제 주사 장치
CN103002896A (zh) 2010-06-16 2013-03-27 布鲁斯·钱德勒·梅 左西替利嗪和孟鲁司特在治疗流感、普通感冒和炎症中的用途
US8496619B2 (en) 2011-07-15 2013-07-30 Antares Pharma, Inc. Injection device with cammed ram assembly
US9220660B2 (en) 2011-07-15 2015-12-29 Antares Pharma, Inc. Liquid-transfer adapter beveled spike
EP4327849A3 (fr) 2012-03-06 2024-04-24 Antares Pharma, Inc. Ampoule-seringue à caractéristique de force de rupture
US9950125B2 (en) 2012-04-06 2018-04-24 Antares Pharma, Inc. Needle assisted jet injection administration of testosterone compositions
WO2013169800A1 (fr) 2012-05-07 2013-11-14 Antares Pharma, Inc. Dispositif d'injection ayant un ensemble piston à came
PT2953667T (pt) 2013-02-11 2020-01-28 Antares Pharma Inc Dispositivo de injeção a jato auxiliado por agulha tendo força de gatilho reduzida
JP6030803B2 (ja) 2013-03-11 2016-11-24 アンタレス・ファーマ・インコーポレーテッド ピニオンシステムを有する用量注射器
WO2014165136A1 (fr) 2013-03-12 2014-10-09 Antares Pharma, Inc. Seringues pré-remplies à volume constant et leurs trousses
RU2015134422A (ru) 2013-03-13 2017-04-18 Инфламматори Респонс Ресёрч, Инк. Применение левоцитиризина и монтелукаста при лечении васкулита
CA2901421A1 (fr) 2013-03-13 2014-10-09 Bruce Chandler May Utilisation de levocetirizine et de montelukast dans le traitement des maladies auto-immunes
CN105517631A (zh) 2013-03-13 2016-04-20 炎症反应研究公司 左西替利嗪和孟鲁司特在治疗创伤性损伤中的用途
JP2017526728A (ja) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004049A1 (fr) * 1990-09-06 1992-03-19 Rijksuniversiteit Te Utrecht Inhibiteurs de la reponse de lymphocytes et de maladies immunitaires
WO1993016724A1 (fr) * 1992-02-28 1993-09-02 Autoimmune, Inc. Suppression de maladies auto-immunes par des antigenes en attente
EP0666080A1 (fr) * 1987-06-24 1995-08-09 Brigham & Women's Hospital Traitement de maladies auto-immunitaires par administration orale d'auto-antigènes
WO1996040235A1 (fr) * 1995-06-07 1996-12-19 Nexstar Pharmaceuticals, Inc. Procede d'utilisation de superantigenes pour cibler des sous-populations de lymphocytes t
WO1996041644A1 (fr) * 1995-06-13 1996-12-27 Nippon Meat Packers, Inc. Medicament a administration par voie orale, contre la polyarthrite rhumatoide et aliment actif

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571499A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5571500A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0666080A1 (fr) * 1987-06-24 1995-08-09 Brigham & Women's Hospital Traitement de maladies auto-immunitaires par administration orale d'auto-antigènes
WO1992004049A1 (fr) * 1990-09-06 1992-03-19 Rijksuniversiteit Te Utrecht Inhibiteurs de la reponse de lymphocytes et de maladies immunitaires
WO1993016724A1 (fr) * 1992-02-28 1993-09-02 Autoimmune, Inc. Suppression de maladies auto-immunes par des antigenes en attente
WO1996040235A1 (fr) * 1995-06-07 1996-12-19 Nexstar Pharmaceuticals, Inc. Procede d'utilisation de superantigenes pour cibler des sous-populations de lymphocytes t
WO1996041644A1 (fr) * 1995-06-13 1996-12-27 Nippon Meat Packers, Inc. Medicament a administration par voie orale, contre la polyarthrite rhumatoide et aliment actif

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AL-SABBAGH, A.M., ET AL.: "Combination of oral antigens with oral methotrexate enhances suppression of autoimmune disease", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 99, no. 1(PART 2), Abs. 99, January 1997 (1997-01-01), pages s24, XP000909440 *
See also references of WO9832451A1 *

Also Published As

Publication number Publication date
KR20000070460A (ko) 2000-11-25
NO993600D0 (no) 1999-07-23
NO993600L (no) 1999-09-23
BR9807112A (pt) 2001-09-18
CA2278152A1 (fr) 1998-07-30
IL131025A0 (en) 2001-01-28
WO1998032451A1 (fr) 1998-07-30
JP2001511134A (ja) 2001-08-07
EP0994717A1 (fr) 2000-04-26
HUP0001960A2 (hu) 2000-10-28
AU6648898A (en) 1998-08-18

Similar Documents

Publication Publication Date Title
IL131025A0 (en) Treatment of autoimmune disease using tolerization in combination with methotrexate
ZA989461B (en) Methods and compositions for the treatment of autoimmune disease using heat shock proteins
ZA9710339B (en) Xanthines and their therapeutic use
HUP0004439A3 (en) 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
EP0924983A4 (fr) S(-)-tolterodine pour le traitement des troubles urinaires et gastro-intestinaux
EP1165109A4 (fr) Traitement de maladie auto-immune
EP0966386A4 (fr) Vehicule a traction humaine
IL139589A0 (en) Use of cyclosporins in the treatment of inflammatory autoimmune diseases
HUP0001276A2 (en) Illuminating body for swimming pools and similar
ZA984174B (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
IL113303A0 (en) Treatment of autoimmune disease using oral tolerization and/or type I interferon
HU9602751D0 (en) Treatment of autoimmune disease using oral tolerization and/or th2-enhancing cytokines
HUP9900147A3 (en) Therapeutic agents and autoimmune diseases
GB9419553D0 (en) Polypeptides and their use in the treatment of auto-immune disease
HK1025954A1 (en) Triptolide derivatives useful in the treatment of autoimmune diseases
EP0797440A4 (fr) Traitement de maladies auto-immunes au moyen de derives de 2-amino purine
GB9621825D0 (en) Microparticles and their use as therapeutic vehicles
GB9705200D0 (en) Well treatment with particles
IL129460A0 (en) Use of lofexidine in the treatment of behavioral disorders
EP1073459A4 (fr) Compositions et methodes visant a induire une tolerance dans l'evolution d'une maladie a mediation assuree par un complexe antigene-anticorps
HUP9902802A3 (en) Pyridyl- and pyrimidyl-piperazines in the treatment of substance abuse disorders
AU7262800A (en) Diagnostic and therapeutic methods in autoimmune disease
EP1020517A4 (fr) Gene issu de chondrocyte humain
IL132845A0 (en) Non-myeloablative tolerogenic treatment
SI0983275T1 (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990818

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20000614

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/505 A, 7A 61K 39/00 B, 7A 61P 37/00 B, 7A 61K 39/00 J, 7A 61K 31:505 J

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000801